Our study aimed to investigate expression and clinical significance of serpin peptidase inhibitor clade A member 3 (SERPINA3) and epidermal growth factor (EGF) containing fibulin-like extracellular matrix protein 2 (EFEMP2) in endometrial carcinoma. A total of 180 patients treated in our hospital from January 2015 to April 2017 were selected as subjects. Positive expression of SERPINA3 was found in 48 cases (80%) in the cancer group, in 6 cases (10%) in the hyperplasia group, and in no case in the control group. The expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia group and control group (P < 0.05). Positive expression of EFEMP2 was found in 10 cases (16.7%) in the cancer group, in 27 cases (45%) in the hyperplasia group, and in 42 cases (70%) in the control group. The expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups (P < 0.05). The protein expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia and control groups (P < 0.05). The protein expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups (P < 0.05). The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis (P < 0.05), but not related to age and tumor size (P > 0.05). SERPINA3 was highly expressed while EFEMP2 was low expressed in endometrial cancer patients. The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis and was hopeful to be one of the detection indexes of endometrial carcinoma.
Introduction
Endometrial carcinoma (EC) is an epithelial malignant tumor occurring in the endometrium and is the second highest incidence of malignant tumors of the female reproductive system. 1 In North America, about 43,470 new patients and 7950 deaths from EC occurred in 2010, ranking first among patients with reproductive system malignancies. In China, with the development of society and the improvement of economic conditions, the incidence of endometrial cancer is increasing year by year, which is only the second of the female genital system malignant tumors next to cervical cancer. Although the prognosis of patients with early EC is ideal, more than 30% of the patients are in the late stage of tumor when diagnosed, among them some patients already have local, pelvic, or even distal metastasis, which results in poor prognosis. 2 Tumor metastasis is the main cause of death in patients, so it is urgent to explore the mechanism of invasion and metastasis of EC cells, and further clarify the development of tumor.
The most common symptom of endometrial cancer is irregular vaginal bleeding. For patients with postmenopausal vaginal bleeding, or that have not been menopausal but with increased menstrual volume, prolonged menstruation, or irregular menstruation, auxiliary ultrasonography, diagnostic curettage, hysteroscopy, magnetic resonance imaging, and tumor markers can assist in early diagnosis and treatment of. 3 Comprehensive treatment based on surgery is mainly taken in the clinic at present. And finding a more sensitive and noninvasive method for early diagnosis, gene targeted therapy, and monitoring of the response to treatment has become the focus of research nowadays. It is generally believed that long-term estrogen stimulation increases the risk of endometrial cancer in the absence of progesterone; however, the specific pathogenesis and development of the disease are still unclear. 4 Tumor recurrence and metastasis are the leading causes of death in cancer patients.
Serpin peptidase inhibitor clade A member 3 (SERPINA3) is a subtype A of serine protease inhibitor family, composed of 423 amino acids, including a signal peptide at the N-terminal and a serine protease inhibitor activity in the serpin domain, with multiple glycosylation sites. SERPINA3 is associated with inflammatory response, Alzheimer's disease, malignant melanoma, gastric cancer, and colon cancer. 5 SERPINA3 can also enter the nucleus, bind to DNA, promote chromatin condensation, and inhibit cell division, in order to block cell proliferation. EGF containing fibulin-like extracellular matrix protein 2 (EFEMP2), also known as fibulin-4, is a member of the fibulin family proteins, mainly involved in the synthesis and arrangement of elastic fibers. EFEMP2 is closely related to skin relaxation, aortic dissection, osteoarthritis, malignant tumors, and other diseases. 6 A previous research has confirmed that SERPINA3 promotes endometrial cancer cell growth by regulating the G2/M cell cycle checkpoint and apoptosis. 7 In addition, some studies have shown that EFEMP2 may be a potential diagnostic marker for EC. 8 At present, research on the relationship between SERPINA3, EFEMP2, and tumor is in the initial stage, and the relationship between SERPINA3 and EFEMP2 and EC has not been understood yet. This study was to explore the expression and clinical significance of SERPINA3 and EFEMP2 in EC tissues.
Materials and methods

General information
A total of 180 patients treated in our hospital from January 2015 to April 2017 were selected as the subjects, with 60 cases of EC (cancer group), 60 cases of atypical hyperplasia of endometrium (hyperplasia group), and 60 cases of normal endometrium (control group). All the studies were approved by the Ethical Committee of Yantai Yuhuangding Hospital and informed consent was obtained from all the patients. The average age of patients was 61.5 ± 2.6 years in the cancer group, 55.3 ± 2.8 years in the hyperplasia group, and 61.3 ± 2.1 years in the control group. There was no significant difference in age between the three groups (P > 0.05).
Specimen source
The specimens of the cancer and hyperplasia groups were derived from pathological specimens before treatment, while the specimens of the control group were derived from uterus that was removed due to dysfunctional uterine bleeding, uterine myoma, and uterine prolapse. The specimens were fixed by formaldehyde solution, embedded by paraffin, and sectioned at 3 μm.
Reagent source
Immunohistochemistry method SABC was used. Both SERPINA3 and EFEMP2 polyclonal antibodies were purchased from Santa Cruz. SABC and DAB kits were purchased from the U.S.A. Bioengineering Co., Ltd. Rabbit antihuman SERPINA3 and EFEMP2 polyclonal antibodies were purchased from Shanghai Xin Hao Biotechnology Co., Ltd.
Immunohistochemistry
Immunohistochemistry was performed by SABC method, and phosphate buffer (PBS) instead of one antibody was used as the negative control. Positive sections provided by the reagent company were used as the positive controls for SERPINA3 and EFEMP2, respectively. All the specimens were evaluated by two pathologists. Two-grade scoring system was adopted. More than five high-field views were selected, and the percentage of positive cells occupied by visual field was counted: 5%-24% for 1 point, more than 25%-49% for 2 points, more than 50%-75% for 3 points, and more than 75% for 4 points. Dyeing intensity classification: light yellow for 1 point, yellow or dark yellow for 2 points, and brown or tan for 3 points. The product of these kinds of scores of more than 1 points meant positive.
Western blot analysis
The endometrial tissues were taken and washed with cold PBS twice, then they were cut into homogenate with pre-cooled lysate, and sonicated by ultrasound. The mixtures were placed at 4°C for 1 h and centrifuged at 12,000 g for 30 min and supernatant was taken. The protein concentration was determined by Lowry method. The amount of total protein used to perform western blot analysis was 30 ug in each group. The samples in each group were electrophoresed through 10% or 15% polyacrylamide gels and transferred onto polyvinylidene difluoride (PVDF) membranes. The membranes were then blocked in 5% BSA for 2 h and incubated overnight at 4°C with primary antibodies for SERPINA3, EFEMP2. After the membranes were washed thrice for 10 min with TBST (10 mM Tris, pH 7.5, 150 mM NaCl, and 0.05% Tween-20), the membranes were incubated with HRP-conjugated secondary antibody at room temperature for 90 min. The specific bands were detected by chemiluminescence. The band intensity was detected and quantified using the ChemiDoc XRS Imaging System.
Statistical analysis
The data were analyzed with SPSS21. 0 software. The measurement data were expressed as mean ± standard deviation (SD) and the t test were used. Chi-square test was used to compare the categorical data. P < 0.05 meant the difference was statistically significant.
Results
Expression of SERPINA3 and EFEMP2 in different endometrial tissues
Positive expression of SERPINA3 was found in 48 cases (80%) in the cancer group, in 6 cases (10%) in the hyperplasia group, and in no case in the control group. The expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia and control groups (P < 0.05). Positive expression of EFEMP2 was found in 10 cases (16.7%) in the cancer group, in 27 cases (45%) in the hyperplasia group, and in 42 cases (70%) in the control group. The expression of EFEMP2 in the cancer group was significantly lower than that in the hyperplasia and control groups (P < 0.05), as shown in Table 1 , Figures 1 and 2 .
Relationship between the expression of SERPINA3 and EFEMP2 and the clinicopathological features of EC
The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis (P < 0.05), but not related to age and tumor size (P > 0.05), as shown in Table 2 . In addition, the protein expression of SERPINA3 in the cancer group was significantly higher than in the other two groups (P < 0.05); conversely, the protein expression of EFEMP2 in the cancer group was significantly lower than in the other two groups (P < 0.05), as shown in Figure 3 .
Discussion
EC is one of the three most common malignant tumors of the female reproductive system, and its incidence is increasing year by year. The incidence of EC is close to cervical cancer, and there is a tendency toward younger patients in EC. At present, the pathogenesis and etiology of EC are still unclear. Therefore, it is of great significance to search for the markers that are involved in the occurrence and development of EC, which would be helpful for the clinical treatment and prognosis of EC. 1 SERPINA3 protein is abnormally expressed in many malignant tumors, but few studies have been done on EC. Yang et al. 7 revealed that the protein expression of SERPINA3 in EC was significantly up-regulated and closely related to pathology in EC with low differentiation and high-stage lymph metastasis, vascular invasion, and negative estrogen receptor, which meant poor prognosis. In this study, the expression of SERPINA3 in the cancer group was significantly higher than that in the hyperplasia and control groups (P < 0.05). It was speculated that SERPINA3 may be involved in the occurrence and development of endometrial cancer. And SERPINA3 protein may promote the proliferation of EC cells by MAPK/ERK1/2 and PI3K/ AKT signal transduction pathway. 9 Human EFEMP2 gene is located near the centromere, located on chromosome 11q13. The translocation, amplification, and rearrangement of this region are related to the development of various malignant tumors. 10 In our study, the expression of EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis (P < 0.05), but not related to age and tumor size (P > 0.05). These suggested that the low expression of EFEMP2 was related to the carcinogenesis of endometrial cells. We hypothesized that overexpression of EFEMP2 may inhibit the invasion and metastasis of EC cells, and the mechanisms remained to be confirmed by extensive studies.
In conclusion, SERPINA3 was highly expressed while EFEMP2 was low expressed in endometrial cancer patients. The expression of SERPINA3 and EFEMP2 in cancer tissues was related to the degree of tumor differentiation, clinical classification, and lymph node metastasis and was hopeful to be one of the detection indexes of EC.
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